Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:BOLD

Audentes Therapeutics (BOLD) Stock Price, News & Analysis

Audentes Therapeutics logo

About Audentes Therapeutics Stock (NASDAQ:BOLD)

Key Stats

Today's Range
$2.69
$2.77
50-Day Range
$59.97
$59.97
52-Week Range
$22.00
$60.00
Volume
50,291 shs
Average Volume
76,621 shs
Market Capitalization
$60.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00
Consensus Rating
Buy

Company Overview

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Audentes Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
50th Percentile Overall Score

BOLD MarketRank™: 

Audentes Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 587th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Audentes Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Audentes Therapeutics has received no research coverage in the past 90 days.

  • Read more about Audentes Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Audentes Therapeutics are expected to grow in the coming year, from ($3.85) to ($3.72) per share.

  • Price to Book Value per Share Ratio

    Audentes Therapeutics has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Audentes Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.49% of the float of Audentes Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Audentes Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Audentes Therapeutics has recently decreased by 20.73%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Audentes Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Audentes Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.49% of the float of Audentes Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Audentes Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Audentes Therapeutics has recently decreased by 20.73%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 3 people have searched for BOLD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
Receive BOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Audentes Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BOLD Stock News Headlines

When it comes to NVDA… “acceleration cycles” are the key
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
Boundless Bio Inc. Common Stock
See More Headlines

BOLD Stock Analysis - Frequently Asked Questions

Audentes Therapeutics Inc (NASDAQ:BOLD) announced its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.74) EPS for the quarter, topping analysts' consensus estimates of ($0.76) by $0.02.

Audentes Therapeutics (BOLD) raised $100 million in an initial public offering (IPO) on Thursday, March 28th 2024. The company issued 6,250,000 shares at a price of $16.00 per share.

Audentes Therapeutics' lock-up period expired on Tuesday, September 24th. Audentes Therapeutics had issued 6,250,000 shares in its public offering on March 28th. The total size of the offering was $100,000,000 based on an initial share price of $16.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.

Based on aggregate information from My MarketBeat watchlists, some other companies that Audentes Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alphabet (GOOG) and Visa (V).

Company Calendar

Last Earnings
11/07/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/06/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BOLD
Fax
N/A
Employees
207
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.00
High Stock Price Target
$25.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+748.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-49,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.40 per share

Miscellaneous

Free Float
21,118,000
Market Cap
$60.43 million
Optionable
No Data
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:BOLD) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners